[{"id":"4b3b972a-c804-49a8-a2d6-60b8eae4c32b","acronym":"KEYNOTE-C62","url":"https://clinicaltrials.gov/study/NCT05860296","created_at":"2023-05-16T17:06:31.720Z","updated_at":"2025-02-25T16:18:48.260Z","phase":"Phase 1/2","brief_title":"Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","source_id_and_acronym":"NCT05860296 - KEYNOTE-C62","lead_sponsor":"SignalChem Lifesciences Corporation","biomarkers":" PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SLC-391"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 05/31/2023","start_date":" 05/31/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-11-19"}]